Table 2.

Viral kinetic parameters and predicted time to cure of patients with shortened treatment.

Pt #	Sex	Age(yr)	Weight(kg)	HCV Gt	Fib	DAA regimen	V0*	c (d-1)	ε	δ (d-1)	Predicted TTC (d)	Actual DAA duration(w)
1	M	54	66	1b	F2	SOF/VEL	6.0	4.2	0.9999	0.25	59	10
2	M	61	104	1b	F3	ELB/GRZ	5.9	11.0	0.9995	0.35	46	8
3**	M	63	84	3a	F0-1	SOF/VEL	6.3	5.6	0.9988	0.5	36	6
4	F	29	55	1b	F0	SOF/LED	6.1	5.2	0.9993	0.25	55	8
5	M	59	71	3	F3	SOF/VEL	5.3	ND	ND	ND	ND	6
6	F	31	46	1B	F0-1	ELB/GRZ	5.2	5.7	0.9994	0.33	43	8
7	F	37	56	1A	F1	ELB/GRZ	6.3	11.2	0.9990	0.45	55	8
8	M	42	85	1B	F0-1	SOF/LED	6.3	4.0	0.9994	0.34	53	8
9	F	65	60	3	F2	SOF/VEL	5.0	7.3	0.9929	0.29	53	8
10	M	35	64	3A	F0-1	SOF/VEL	6.3	4.4	0.9993	0.41	44	8
11	F	67	80	1B	F1	ELB/GRZ	5.2	3.3	0.9999	0.28	53	8

*V₀, initial viral load (log IU/ml) was set during fitting based on each patient’s measured baseline HCV RNA; **, relapser; Fib, Fibrosis stage; Gt, genotype; DAA, direct-acting antiviral; SOF/VEL, sofosbuvir/velpatasvir; SOF/LED, sofosbuvir/ledipasvir; ELB/GRZ, elbasvir/grazoprevir; TTC, Time to cure; ND, not determined because viral load was < 10 IU/ml at day 2 of therapy.